Q-omics provides the consensus-scored RN7SL73P profile across patient tissues and cancer cell-line models. RN7SL73P expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, RN7SL73P is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, RN7SL73P RNA expression shows 7,026 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight PAAD, BRCA, and SARC as cancer lineages where RN7SL73P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SL73P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SL73P survival associations across molecular data types. RN7SL73P RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SL73P RNA expression–survival associations across cancer types. High RN7SL73P expression shows unfavorable associations in MESO, BLCA, DLBC, KICH and KIRC, but favorable associations in PAAD. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify PAAD as the clearest survival context for RN7SL73P RNA expression.
This table summarizes RN7SL73P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SL73P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SL73P shows lower tumor expression in BRCA and higher tumor expression in UCEC, LUSC, STAD and KIRC. The BRCA box plot shows higher RN7SL73P RNA expression in normal versus tumor tissue (log2 FC = −0.072, t-test p = .012).
This table shows molecular features associated with RN7SL73P in patient tissues and cancer cell lines. In patient samples, RN7SL73P shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set.
